Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study

Hormones and Cancer

Volumn 7, Issue 3, 2016, Pages 178-187

  Clendenen, Tess V ^a   Hertzmark, Kathryn ^a   Koenig, Karen L ^a   Lundin, Eva ^b   Rinaldi, Sabina ^c   Johnson, Theron ^d   Krogh, Vittorio ^e   Hallmans, Göran ^b   Idahl, Annika ^b   Lukanova, Annekatrin ^d   Zeleniuch Jacquotte, Anne ^a,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; BIOLOGICAL MARKER;

ADULT; AGE; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BLOOD DONOR; BODY MASS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTRACEPTIVE BEHAVIOR; CONTROL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MIDDLE AGED; NULLIPARA; PREMENOPAUSE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; AGED; BLOOD; ENDOMETRIAL NEOPLASMS; PROSPECTIVE STUDY; RISK;

ADULT; AGED; ANDROGENS; BIOMARKERS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROSPECTIVE STUDIES; RISK;

EID: 84959337080     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-016-0258-1     Document Type: Article

References (41)

1. Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57(2):205–212
2. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531–1543
3. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84:975–981
4. Lukanova A, Lundin E, Micheli A, Arslan AA, Ferrari P, Rinaldi S, Krogh V et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108:425–432
5. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17(4):921–929. doi:10.1158/1055-9965.EPI-07-2686
6. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH et al (2008) Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Rel Cancer 15(2):485–497
7. Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC (2013) Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids 78(1):96–101. doi:10.1016/j.steroids.2012.10.010
8. Mushayandebvu T, Castracane VD, Gimpel T, Adel T, Santoro N (1996) Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Fertil Steril 65(4):721–723
9. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML et al (1996) Case–control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88(16):1127–1135
10. Prodi G, Nicoletti G, De Giovanni C, Galli MC, Grilli S, Nanni P, Gola G, Rocchetta R, Orlandi C (1980) Multiple steroid hormone receptors in normal and abnormal human endometrium. J Cancer Res Clin Oncol 98(2):173–183
11. Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A et al (2001) Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 10(7):757–765
12. Rinaldi S, Plummer M, Biessy C, Castellsague X, Overvad K, Kruger Kjaer S, Tjonneland A et al (2011) Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomarkers Prev 20(12):2532–2540. doi:10.1158/1055-9965.EPI-11-0753
13. Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjonneland A, Olsen A et al (2014) Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—results from the EPIC cohort. Int J Cancer 134(8):1947–1957. doi:10.1002/ijc.28528
14. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R (2002) Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1065–1071
15. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC et al (2005) Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 111(10):1242–1249. doi:10.1161/01.CIR.0000157697.54255.CE
16. Hong C-C, Tang B-K, Rao V, Agarwal S, Martin L, Tritchler D, Yaffe M, Boyd N (2004) Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res 6(4):R338–R351
17. van Buuren S (2007) Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 16(3):219–242. doi:10.1177/0962280206074463
18. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749. doi:10.1210/jc.2003-032046
19. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84(11):4006–4011. doi:10.1210/jcem.84.11.6148
20. Michelmore KF, Balen AH, Dunger DB, Vessey MP (1999) Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51(6):779–786
21. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85(7):2434–2438. doi:10.1210/jcem.85.7.6682
22. Hamilton-Fairley D, Taylor A (2003) Anovulation. BMJ 327(7414):546–549. doi:10.1136/bmj.327.7414.546
23. Chandeying P, Pantasri T (2015) Prevalence of conditions causing chronic anovulation and the proposed algorithm for anovulation evaluation. J Obstet Gynaecol Res. doi:10.1111/jog.12685
24. Revised (2003) consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. 2004. Fertil Steril 81(1):19–25
25. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456–488. doi:10.1016/j.fertnstert.2008.06.035
26. Homburg R (2009) Androgen circle of polycystic ovary syndrome. Hum Reprod 24(7):1548–1555. doi:10.1093/humrep/dep049
27. Jonard S, Dewailly D (2004) The follicular excess in polycystic ovaries, due to intra‐ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10(2):107–117. doi:10.1093/humupd/dmh010
28. Rosner W, Auchus R, Azziz R, Sluss P, Raff H (2007) Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92(2):405–413
29. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G (2012) Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 97(2):408–415. doi:10.1210/jc.2011-2134
30. Keefe CC, Goldman MM, Zhang K, Clarke N, Reitz RE, Welt CK (2014) Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS ONE 9(4):e93805. doi:10.1371/journal.pone.0093805
31. Missmer S, Spiegelman D, Johnson EB, Barbieri R, Pollak M, Hankinson S (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978
32. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M, Arslan AA, Toniolo P, Shore RE, Koenig KL (2012) Premenopausal serum androgens and breast cancer risk: a nested case–control study. Breast Cancer Res 14(1):R32. doi:10.1186/bcr3117
33. Rose GL, Dowsett M, Mudge JE, White JO, Jeffcoate SL (1988) The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro. Fertil Steril 49(2):224–228
34. Tuckerman EM, Okon MA, Li T, Laird SM (2000) Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril 74(4):771–779
35. Neulen J, Wagner B, Runge M, Breckwoldt M (1987) Effect of progestins, androgens, estrogens and antiestrogens on 3H-thymidine uptake by human endometrial and endosalpinx cells in vitro. Arch Gynecol 240(4):225–232
36. Park SB, Han M (2013) Inhibitory effects of androstenedione on endometrial cells: implications for poor reproductive outcome among women with androgen excess. Eur J Obstet Gynecol Reprod Biol 171(2):295–300. doi:10.1016/j.ejogrb.2013.09.022
37. Miller N, Bedard YC, Cooter NB, Shaul DL (1986) Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology 10(7):661–669
38. Grynberg M, Fanchin R, Dubost G, Colau JC, Bremont-Weil C, Frydman R, Ayoubi JM (2010) Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 20(4):553–558. doi:10.1016/j.rbmo.2009.12.021
39. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P et al (2009) Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 6(11):3193–3200. doi:10.1111/j.1743-6109.2009.01380.x
40. Zang H, Sahlin L, Masironi B, Eriksson E, Linden Hirschberg A (2007) Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 92(6):2169–2175. doi:10.1210/jc.2006-2171
41. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 15(5):972–978. doi:10.1158/1055-9965.EPI-05-0848